Clinical manifestations of familial medullary thyroid carcinoma

Kaori Kameyama, Hiroko Okinaga, Hiroshi Takami

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


We conducted a large-scale nation-wide questionnaire survey to ascertain the status of familial medullary thyroid carcinoma (MTC) in Japan in 2002. Out of a total of 271 MTC cases (male to female ratio 1:1.4), multiple endocrine neoplasia (MEN) 2A accounted for 83 cases (30.6%), familial MTC (FMTC) for 14 cases (5.1%), MEN for 11 cases (4.1%), and sporadic MTC for 163 cases (60.1%). Mean age at the time of diagnosis was 35.6 in MEN2A, 34.6 in FMTC, 30.5 in MEN2B, and 47.6 in sporadic MTC. Forty-five percent of MEN2A patients had pheochromocytoma and 11% of MEN2A patients had parathyroid disorders when MTC was diagnosed. Finally, the RET oncogene test yielded the largest number of initial findings that led to diagnosis of familial MTC.

Original languageEnglish
Pages (from-to)348-350
Number of pages3
JournalBiomedicine and Pharmacotherapy
Issue number6-7
Publication statusPublished - 2004 Jun


  • Familial cancer
  • Medullary thyroid carcinoma
  • RET protooncogene

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Clinical manifestations of familial medullary thyroid carcinoma'. Together they form a unique fingerprint.

Cite this